Understanding Maintenance Therapy for Multiple Myeloma

What is Multiple Myeloma?

Multiple Myeloma (MM) is a type of cancer that originates in the plasma cells, which are a crucial part of your immune system found in the bone marrow. These plasma cells normally produce antibodies to help your body fight infections. In multiple myeloma, these plasma cells become cancerous, grow uncontrollably, and accumulate in the bone marrow, crowding out healthy blood cells. This can lead to a range of health problems. The American Cancer Society estimates that a significant number of new MM diagnoses occur each year, highlighting its importance as a health concern.

The Role of Maintenance Therapy in Multiple Myeloma Treatment

The treatment journey for multiple myeloma is often multi-phased. After initial treatments, which may include chemotherapy, targeted therapy, or a stem cell transplant, a phase known as maintenance therapy may be recommended. The primary goals of maintenance therapy are to keep the multiple myeloma in remission and to prevent the disease from progressing or returning. It's a strategy aimed at long-term disease control and improving the quality of life for patients.

Goals of Maintenance Therapy

• Suppressing Cancer Cell Growth: The main objective is to keep the number of myeloma cells as low as possible after the initial intensive treatment has reduced them.
• Preventing Progression: Maintenance therapy aims to stop or significantly slow down the return or worsening of the disease.
• Maintaining Remission: It helps to prolong the period of remission, where the signs and symptoms of cancer are reduced or absent.

Ideally, maintenance therapy is continued for an extended period, often until the disease shows signs of progression. However, the duration can vary based on individual patient factors, tolerance to the medication, and the emergence of side effects.

Maintenance Therapy Options for Multiple Myeloma

The choice of maintenance therapy depends heavily on the individual's risk status, which can be categorized as standard risk or high risk. This risk stratification is based on specific genetic markers within the cancer cells, such as chromosomal abnormalities, as well as the stage of the disease and the patient's overall health.

Standard Risk Multiple Myeloma

For individuals diagnosed with standard risk multiple myeloma, the most commonly prescribed maintenance therapy involves a single drug called lenalidomide (brand name Revlimid). Lenalidomide belongs to a class of drugs known as immunomodulatory drugs (IMiDs). These drugs work by modifying the immune system's activity to help it fight cancer cells more effectively. They also possess direct anti-myeloma properties, directly inhibiting the growth and survival of myeloma cells.

High Risk Multiple Myeloma

Patients with high risk multiple myeloma often have a more aggressive form of the disease, which may lead to poorer outcomes. For these individuals, the maintenance therapy regimen is typically more intensive. It often involves a combination of drugs, frequently including lenalidomide along with a proteasome inhibitor, such as bortezomib (brand name Velcade). Proteasome inhibitors work by blocking the function of proteasomes within cells. Proteasomes are responsible for breaking down and removing damaged or unnecessary proteins. By inhibiting proteasomes, these drugs cause a buildup of toxic proteins within the cancer cells, leading to their death.

Research continues to explore various drug combinations for maintenance therapy, aiming to find the most effective regimen that maximizes remission duration and minimizes side effects. Studies have shown that while some newer drug combinations can improve progression-free survival (PFS), their impact on overall survival (OS) might be less pronounced. A 2023 study involving patients with high-risk MM who had undergone a stem cell transplant evaluated lenalidomide alone, bortezomib alone, or a combination of both. The findings indicated that patients receiving bortezomib-based therapy were more likely to have factors associated with a less favorable prognosis.

Potential Side Effects of Maintenance Therapy

Like all medical treatments, maintenance therapy for multiple myeloma can cause side effects. The specific side effects depend on the drugs used, the dosage, and individual patient tolerance. Common side effects associated with lenalidomide can include fatigue, diarrhea, rash, and an increased risk of blood clots. Bortezomib can cause side effects such as peripheral neuropathy (nerve damage causing numbness or tingling in the hands and feet), fatigue, and gastrointestinal issues.

It is crucial for patients to communicate openly with their healthcare team about any side effects they experience. Adjustments to the dosage or the treatment regimen may be necessary to manage these side effects and ensure the therapy remains tolerable and effective.

When to Consult a Doctor

It is essential to consult with your oncologist or hematologist regularly throughout your maintenance therapy. You should seek medical advice if you experience any:

• New or worsening symptoms of multiple myeloma.
• Significant or unmanageable side effects from the medication.
• Concerns about your treatment plan or its effectiveness.
• Any other new or concerning health issues.

Regular monitoring and open communication with your healthcare provider are key to successfully managing multiple myeloma with maintenance therapy.